Posted on Oct. 16: McMaster receives $1-million for national arthritis treatment program

McMaster University, in conjunction with St. Joseph's Healthcare Hamilton, has announced a major funding commitment of $1 million from Pharmacia Canada Inc. and Pfizer Canada Inc. for an innovative educational initiative called the Arthritis Treatment Program. Funded over five years, the program will be designed to assist primary care physicians and other health professionals in providing optimal care for people with arthritis. "This is an excellent example of innovation in the relationship between the pharmaceutical industry, health care providers and universities, where our interests mesh well," said John Kelton, dean and vice-president, Faculty of Health Sciences at McMaster University. "Funding of the Arthritis Treatment Program clearly supports a commitment to excellence in health care education. By enhancing current medical training, the program will support better diagnosis and treatment for millions of Canadians with arthritis." More than four million Canadians, or one in every seven individuals, suffer from some form of arthritis. That number is expected to grow at a rate of one million more Canadians per decade, at least until the year 2031. Led by one of Canada's leading clinical rheumatologists, William Bensen, and a team of rheumatologists at McMaster and its partner institution, St. Joseph's Healthcare Hamilton, the Arthritis Treatment Program will consist of an overall practical management package including concepts and tools for managing rheumatoid arthritis and osteoarthritis. A simple, easy-to-use measurement tool will be developed for use in clinical practice that provides a common language between physician and patient and acts as a benchmark for improving arthritis care.

Read More